Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CFO | March 03, 2022 | March 04, 2022 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director · Interim CFO | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date March 03, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,819 |
Ending reported balance
After 2022-03-03 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2022-03-03 · Exercise / conversion · Acquired 3,846 · Balance 29,665 Row 2 · 2022-03-03 · Exercise / conversion · Acquired 3,304 · Balance 32,969 Row 3 · 2022-03-03 · Exercise / conversion · Acquired 1,815 · Balance 34,784 Row 4 · 2022-03-03 · Sale · Disposed 3,825 · Balance 30,959 F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2022-03-03 · Sale · Disposed 2,606 · Balance 28,353 F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2022-03-03 · Sale · Disposed 1,289 · Balance 27,064 F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2022-03-03 · Sale · Disposed 858 · Balance 26,206 F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2022-03-03 · Sale · Disposed 387 · Balance 25,819 F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.34 · Expires 2023-02-23 | Direct | 0 |
Reported balance
After 2022-03-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-03 · Exercise / conversion · Disposed 3,846 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $144.67 · Expires 2024-02-22 | Direct | 3,305 |
Reported balance
After 2022-03-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-03-03 · Exercise / conversion · Disposed 3,304 · Balance 3,305 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.66 · Expires 2030-05-29 | Direct | 5,446 |
Reported balance
After 2022-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-03-03 · Exercise / conversion · Disposed 1,815 · Balance 5,446 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Fortrea Holdings Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 28,692 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 15,840 · Balance 28,692 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service. F3: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock").
F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service.
F3: This number reflects the aggregate number of RSUs held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.10 | $14,010.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 26 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,620 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.03 | $14,003.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 25 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,720 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.98 | $13,998.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 24 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,820 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.94 | $13,994.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 23 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,920 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.92 | $13,992.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 22 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,020 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.88 | $13,988.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 21 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,120 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.85 | $13,985.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 20 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,220 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.82 | $13,982.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 19 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,320 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.80 | $13,980.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 18 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,420 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.79 | $13,979.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 17 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.77 | $13,977.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 16 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,620 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.75 | $13,975.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 15 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,720 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $139.70 | $55,880.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 14 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,820 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $139.69 | $41,907.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 13 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,220 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.65 | $13,965.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 12 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,520 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.64 | $13,964.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 11 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,620 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 750 | $139.62 | $104,713.80 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 10 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,720 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.61 | $13,961.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 9 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.59 | $13,959.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 8 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,570 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.58 | $13,958.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.57 | $13,957.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,770 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.56 | $13,956.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,870 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.51 | $13,951.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.46 | $13,946.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,070 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.32 | $13,932.00 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,170 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,187 | $73.70 | $308,581.90 |
DisclosureSEC source: 0001127602-19-008788 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $143.84 | $14,384.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 15 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,633 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $143.67 | $14,367.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 14 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,733 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $143.14 | $10,019.80 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 13 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,833 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $143.10 | $14,310.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 12 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,903 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $141.98 | $14,198.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 11 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,003 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $141.73 | $14,173.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 10 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,103 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $141.35 | $28,270.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 9 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,203 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $141.34 | $14,134.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 8 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,403 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.78 | $14,078.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,503 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.60 | $14,060.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,603 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.50 | $14,050.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,703 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.42 | $14,042.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,803 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 117 | $140.39 | $16,425.63 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,903 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.35 | $14,035.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,020 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $140.33 | $14,033.00 |
DisclosureSEC source: 0001127602-19-008790 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,120 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $146.05 | $14,605.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 23 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,462 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $146.01 | $29,202.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 22 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,562 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $146.00 | $43,800.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 21 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,762 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.93 | $29,186.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 20 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.83 | $14,583.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 19 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,262 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.82 | $14,582.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 18 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,362 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.61 | $14,561.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 17 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,462 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.53 | $29,106.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 16 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,562 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.52 | $29,104.00 |
DisclosureSEC source: 0001127602-19-008352 · form4.xml · nonDerivative · entry 15 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.